Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis

**Study Design: ADvocate1 and ADvocate2**

- **Induction Period**: 4 weeks
- **Maintenance Treatment Period**: 12 weeks
- **Randomization 1:2**: 1:2 PBO, N=287
- **EASI clinical sign by body region scores and itch data**

---

**EASI Clinical Sign Score Percent Improvement From Baseline Through Week 16**

- **ADvocate1 (ITT)**: Significant Improvement With Lebrikizumab First Seen by Week 2 in All Regions for All Clinical Signs
- **ADvocate1 and ADhere (mITT)** (See Supplementary Data)
  - For Advanced, significant improvement with lebrikizumab treatment was first seen by Week 2
  - For erythema and papulation by Week 3 in the trunk and upper extremities and by Week 4 in lower extremities
  - For excoriation by Week 4 in all regions
- **ADvocate2**: Significant improvement was first seen for lichenification by Week 2 and for papulation by Week 3, continuing at Week 6

---

**Supplementary Data: ADvocate2 and ADhere Results**

- **Key Eligibility Criteria**
  - Adult or adolescent (12 to 18 years; weight ≥40 kg)
  - Diagnosis of AD defined by the National Academy of Dermatology Consensus Criteria
  - Moderate-to-severe AD, defined as having all the following at the baseline visit:
    - EASI ≥16
    - IGA score ≥3
    - At least 40% involvement
  - Candida for systemic therapy

- **Outcomes**
  - EASI clinical sign by body region
  - Disease activity scores and daily Pruritus NRS were set to missing after rescue medication or treatment discontinuation

---

**Statistical Analysis**

- **Analysis Populations**
  - Patients with ≥10% EASI improvement from baseline in Pruritus NRS were included in the final analysis population

- **Statistical Methods**
  - EASI clinical sign by body region
  - Disease activity scores and daily Pruritus NRS were set to missing after rescue medication or treatment discontinuation
  - rescue medication or treatment discontinuation was analyzed using the last observed value approach
  - The EASI total score was analyzed using the last observed value approach

---

**RESULTS**

- **Baseline Demographics and Disease Characteristics**
  - **ADvocate1**
  - **ADvocate2**
  - **ADhere**

---

**DISCLOSURES**

- **REFERENCES**

---

**METHODS**

- **Study Design: ADvocate1 and ADvocate2**
  - **Induction Period**: 4 weeks
  - **Maintenance Treatment Period**: 12 weeks
  - **Randomization 1:2**: 1:2 PBO, N=287

---

**REFERENCES**

- Eric Simpson,1 Gil Yosipovitch,2 Kilian Eyerich,3 Delphine Staumont-Salle,4 Mona Shahriari,5 Gaia Gallo,6 Eric Wolf,6 Evangeline Pierce,6 Chunyu Liu,7 Jinglin Zhong,8 Helena Agell,9 Marjolein de Bruin-Weller10
- 1Oregon Health & Science University, Portland, USA; 2University of Miami Miller School of Medicine, Miami, USA; 3University of Freiburg, Germany; 4University of Lille, Lille, France; 5Yale University School of Medicine, New Haven, USA; 6Eli Lilly and Company, Indianapolis, USA; 7TigerMed Inc, Somerset, USA; 8IQVIA, Durham, USA; 9Aimantil, S.A., Barcelona, Spain; 10University Medical Center Utrecht, The Netherlands